A new study shows that a single injection of specially designed nanoparticles can dramatically reduce levels of a toxic ...

Every few weeks, a 65-year-old man named Rick drives an hour and a half from his home in New Hampshire to Brigham and Women’s Hospital in Boston, where a nurse inserts a needle in his arm and a clear ...

"We're so close." Dr. Miriam Merad says NIH cuts could derail life-saving cancer research just as scientists close in on new ...

A study published in Science reveals a cellular mechanism involved in the inheritance of genetic mutations. The study also ...

The time to carry out diagnostic MRI scans for dementia can be cut to one-third of their standard length, according to a new ...

With U.S. diagnoses of Parkinson's expected to reach 1.2 million by 2030, research is in full swing, and treatments ...

Although teplizumab doesn’t work for everyone and how much it delays progression varies, it has inspired new directions in ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

Medication has long been the cornerstone of treatment for people with epilepsy, but it doesn't stop seizures for everyone and ...